Tests semaglutide or tirzepatide in young people who lost less weight after surgery
Tests semaglutide or tirzepatide in people with obesity who lost less weight after surgery.
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Registry title
- Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 40 people, planned
- Started
- 11 Oct 2024
- Expected to end
- 1 Oct 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Injectable semaglutide or injectable tirzepatide
- Standard postoperative care
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 to 24 who are getting or have had vertical sleeve gastrectomy weight-loss surgery. Some later take semaglutide or tirzepatide if weight loss after surgery is lower than expected.
- Age
- 12 to 24 years
- Sex
- Males and females can join.
- Disease stage
- Observation phase: in the preoperative pathway for vertical sleeve gastrectomy. Treatment phase: after vertical sleeve gastrectomy, with obesity (age 12-17: BMI at or above the 95th percentile for age and sex; age 18-24: BMI of 30 kg/m^2 or more).
- Earlier treatment
- Treatment phase: vertical sleeve gastrectomy, with 22% or less BMI loss at 6-24 months after surgery. Recent use of oral glucocorticoids, metformin, insulin secretagogues or anti-obesity medicines is not allowed, and current use of insulin is not allowed.
Main reasons for not taking part
- Type 2 diabetes
- Hypothalamic obesity
- Planned Roux-en-Y gastric bypass (observation phase)
- Personal or family history of medullary thyroid carcinoma, or history of pancreatitis (treatment phase)
- Current pregnancy, or plan to become pregnant in the next 8 months (treatment phase)
The registry criteria, word for word
Show all 45 criteriaShow less
Who can take part
- Signed and dated informed consent form
- Willingness to comply with all study procedures and availability for the duration of the study
- Male or female biological sex, age 12 through 24 years
- In the preoperative pathway for vertical sleeve gastrectomy
- Signed and dated informed consent form
- Status post vertical sleeve gastrectomy
- Male or female biological sex, age 12 through 24 years
- Meeting minimum nutrition goals
- Obesity: age 12-17 years: BMI ≥95th%ile for age/sex | age 18-24 years: BMI ≥ 30kg/m\^2
- If entering the Intervention phase from the Observational phase: ≤22% BMI loss at 6-24 months postop
- If entering the Intervention phase from the existing patient pool: ≤22% BMI loss at 6-24 months postop
Who cannot take part
- Intentional self-harm within the previous 1 month
- Recent change to concomitant medications for hypertension, dyslipidemia, depression or anxiety (<4 weeks prior to enrollment)
- Use of insulin secretagogues (within 4 half-lives of the medication of baseline visit)
- Use of anti-obesity medications (within 4 half-lives of the medication of baseline visit)
- For females of reproductive potential: Not on contraception (i.e. two forms of birth control for example oral birth control pills and condoms) for at least 1 month prior to enrollment and agreement to use these during study participation and for an additional 8 weeks after the final dose of study medication
- Type 2 Diabetes
- Known hypersensitivity to any component of semaglutide
- Personal or family history of medullary thyroid carcinoma
- Personal history of multiple endocrine neoplasia type 2
- Type 2 Diabetes
- History of pancreatitis
- Uncontrolled hypertension
- Clinically significant arrhythmia or heart disease that could be exacerbated by increased heart rate
- Malignant neoplasm within the last 5 years
- Untreated thyroid disorder
- Active major psychiatric disorder limiting informed consent
- Baseline alanine transaminase (ALT) or aspartate aminotransferase (AST) ≥ 5x upper limit of normal
- Baseline Creatinine >1.2mg/dL
- Planned Roux-en-Y gastric bypass
- Hypothalamic obesity
- Current use of oral glucocorticoids (i.e. within 10 days of baseline visit)
- Current use of insulin; Intervention/Treatment Phase
- Surgically correctable cause of suboptimal postoperative weight loss
- Hypothalamic Obesity
- Tanner Stage 1
- Active treatment for bulimia nervosa
- Suicidal ideation of type 4 or 5 on Columbia-Suicide Severity Rating Scale (C-SSRS)
- Severe unmanaged depression, defined by Center for Epidemiological Studies Depression (CESD) score of 26 or greater and by clinical evaluation
- Use of oral glucocorticoids (within 10 days of baseline visit)
- Use of metformin (within 3 months of baseline visit)
- Current use of insulin
- Current pregnancy
- For females of reproductive potential: Plan to become pregnant in the next 8 months
Other criteria
- Observation Phase
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 24 years old?
Where in United States
- Childrens Hospital ColoradoAurora, United StatesContact: Jaime Moore, MD MPHTaking people
About the trial
What the trial wants to find out
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond weight loss alone. The study also plans to learn more about whether a medication (semaglutide or tirzepatide) can help people 12 to 24 years old who, between 6 and 24 months after bariatric surgery, have not lost as much weight as expected.
The 3 groups in the trial
- ObservationalNo study treatment, for comparison
Participants complete a set of standardized measures before bariatric surgery, 3 months postoperatively, and 6 months postoperatively.
- Active Medication + Standard Postoperative CareTreatment being tested
Participants can be enrolled between 6 and 24 months postoperatively and will receive usual interdisciplinary postoperative care plus weekly subcutaneous injectable semaglutide or tirzepatide for 26 weeks. Initial dose is 0.25mg (semaglutide) or 2.5mg (tirzepatide) and is escalated every 4 weeks as tolerated up to the max dose of 2.4mg for semaglutide or 15mg for tirzepatide for a total exposure of 26 weeks.
Treatment: Injectable semaglutide or injectable tirzepatide and Standard postoperative care
- Standard Postoperative CareExisting treatment, for comparison
Participants can be enrolled between 6 to 24 months postoperatively and will receive usual interdisciplinary postoperative care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial)
- Plain-language title
- Tests semaglutide or tirzepatide in young people who lost less weight after surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06575738, who can take part
- Record updated
- 15 July 2026